A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects
Phase 1
Completed
- Conditions
- IgA NephropathyParoxysmal Nocturnal Hemoglobinuria
- Interventions
- Drug: HRS-5965 Capsules
- Registration Number
- NCT07035665
- Lead Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
- Brief Summary
- The study is being conducted to evaluate the effect of food on pharmacokinetics of HRS-5965 capsules after oral administration. 
- Detailed Description
- Not available 
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
- Signed the informed consent form pre-trial.
- Aged 18-45 years at signing the informed consent form.
- Childbearing potential subjects: no pregnancy/sperm/egg donation plans; effective contraception.
Exclusion Criteria
- Recent infection (≤2 weeks): pathogen-positive test, systemic antibiotics, or fever > 38°C.
- Major trauma/surgery (≤8 weeks) or planned surgery during the study.
- Drug abuse history or positive urine drug screen.
- Investigator-assessed suitability concerns: increased risk, compliance issues, or clinical ineligibility.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
- Group - Intervention - Description - HRS-5965 Group A - HRS-5965 Capsules - - - HRS-5965 Group B - HRS-5965 Capsules - - 
- Primary Outcome Measures
- Name - Time - Method - Peak concentration (Cmax) of HRS-5965 - Day 1 to Day 13. - Area under the plasma concentration - time curve from time 0 to the last quantifiable timepoint (AUC0-t) - Day 1 to Day 13. 
- Secondary Outcome Measures
- Name - Time - Method - Time to peak concentration (Tmax) - Day 1 to Day 13. - Adverse events (AEs) - Day 1 to Day 20. 
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the molecular mechanism of HRS-5965 in modulating IgA production and complement activation in IgA nephropathy?
How does HRS-5965 compare to standard-of-care treatments like corticosteroids in IgA nephropathy clinical outcomes?
Which biomarkers are associated with response to HRS-5965 in patients with paroxysmal nocturnal hemoglobinuria and IgA nephropathy?
What are the potential adverse events of HRS-5965 and how do they compare to other C3 inhibitors in PNH treatment?
Are there any combination therapies involving HRS-5965 and eculizumab that enhance therapeutic efficacy in PNH?
Trial Locations
- Locations (2)
- ZhongShan Hospital FuDan University 🇨🇳- Shanghai, Shanghai, China - ZhongShan Hospital FuDan University 🇨🇳- Shanghai, Shanghai, China ZhongShan Hospital FuDan University🇨🇳Shanghai, Shanghai, ChinaXuening LiPrincipal Investigator
